N = 9147 | Estimate | Std. Error | t value | Pr(>|t|) | |
---|---|---|---|---|---|
(Intercept) | − 4388.13 | 1956.20 | −2.24 | 0.0249* | |
Age | 55 < 65 | 366.80 | 667.03 | 0.55 | 0.5824 |
65 < 75 | 23.96 | 622.49 | 0.04 | 0.9693 | |
≥ 75 | − 1479.16 | 628.26 | −2.35 | 0.0186* | |
Gender | female | − 182.06 | 298.09 | −0.61 | 0.5414 |
BMI | underweight | 760.97 | 1784.07 | 0.43 | 0.6697 |
overweight | −105.89 | 352.11 | −0.30 | 0.7636 | |
obese | − 177.73 | 380.95 | −0.47 | 0.6408 | |
BIMD 2010 (Q1 least deprived, Q5 most deprived) | Q2 | − 342.96 | 410.99 | − 0.83 | 0.4040 |
Q3 | −745.28 | 441.27 | −1.69 | 0.0913 | |
Q4 | − 299.33 | 436.92 | −0.69 | 0.4933 | |
Q5 | − 781.20 | 414.84 | −1.88 | 0.0597 | |
Smoker | yes | −49.90 | 431.94 | −0.12 | 0.9080 |
NYHA | 1 | 2580.50 | 776.13 | 3.32 | 0.0009*** |
2 | 1378.37 | 463.25 | 2.98 | 0.0029** | |
3 | 2809.18 | 417.38 | 6.73 | 0.0000*** | |
4 | 4422.92 | 440.04 | 10.05 | 0.0000*** | |
DMP COPD | yes | 1042.85 | 498.59 | 2.09 | 0.0365* |
DMP asthma | yes | − 759.08 | 841.90 | − 0.90 | 0.3673 |
DMP diabetes type 1 | yes | 2033.06 | 2326.11 | 0.87 | 0.3821 |
DMP diabetes type 2 | yes | 505.34 | 276.79 | 1.83 | 0.0679 |
deceased | yes | 10,472.27 | 911.95 | 11.48 | 0.0000*** |
HMG assignments per month | 1.23 | 0.24 | 5.18 | 0.0000*** | |
Year after AMI | − 5722.92 | 162.81 | −35.15 | 0.0000*** | |
days insured | 42.73 | 4.86 | 8.79 | 0.0000*** | |
Angina pectoris | 2027.02 | 270.66 | 7.49 | 0.0000*** | |
Peripheral vascular disease | 4179.64 | 382.42 | 10.93 | 0.0000*** | |
Dyslipidemia | 498.35 | 352.61 | 1.41 | 0.1576 | |
Congestive heart failure | 2090.90 | 339.30 | 6.16 | 0.0000*** | |
Hypertension | 1867.35 | 556.62 | 3.35 | 0.0008*** | |
Dialysis | 23,977.62 | 964.93 | 24.85 | 0.0000*** | |
edf | Ref.df | F | p-value | ||
s (PDC mean ACE inhibitors) male | 1.04 | 1.04 | 0.01 | 0.9423 | |
s (PDC mean ACE inhibitors) female | 1.00 | 1.00 | 0.89 | 0.3465 | |
s (PDC mean β-blockers) male | 1.00 | 1.00 | 2.70 | 0.1003 | |
s (PDC mean β-blockers) female | 1.00 | 1.00 | 0.32 | 0.5704 | |
s (PDC mean statins) male | 1.65 | 1.65 | 1.87 | 0.0949 | |
s (PDC mean statins) female | 1.00 | 1.00 | 1.61 | 0.2044 | |
s (PDC mean anti-platelet agents) male | 2.49 | 2.49 | 18.84 | 0.0000*** | |
s (PDC mean anti-platelet agents) female | 3.38 | 3.38 | 6.26 | 0.0003*** | |
s (PDC standard deviation ACE inhibitors) male | 2.35 | 2.35 | 1.73 | 0.1356 | |
s (PDC standard deviation ACE inhibitors) female | 2.72 | 2.72 | 6.54 | 0.0005*** | |
s (PDC standard deviation β-blockers) male | 3.63 | 3.63 | 12.74 | 0.0000*** | |
s (PDC standard deviation β-blockers) female | 1.00 | 1.00 | 2.89 | 0.0893 | |
s (PDC standard deviation statins) male | 1.00 | 1.00 | 0.43 | 0.5129 | |
s (PDC standard deviation statins) female | 3.58 | 3.58 | 3.73 | 0.0107* | |
s (PDC standard deviation anti-platelet agents) male | 4.05 | 4.05 | 4.77 | 0.0007*** | |
s (PDC standard deviation anti-platelet agents) female | 2.79 | 2.79 | 4.54 | 0.0059** |